UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2023

Commission File Number: 001-40299

 

 

Achilles Therapeutics plc

(Exact name of registrant as specified in its charter)

 

 

245 Hammersmith Road

London W6 8PW

United Kingdom

Tel: +44 (0)20 8154 4600

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

 

 

 

Results of Annual General Meeting

On June 28, 2023, Achilles Therapeutics plc (“Achilles” or the “Company”) held its 2023 Annual General Meeting (the “Annual General Meeting”), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on May 26, 2023 were duly proposed and passed on a poll.

The matters presented for a vote and the related results are as follows:

 

Ordinary Resolutions    For      Against      Abstain  

To re-elect Edwin Moses as a Director of the Company.

      8,617,511        1,477,612        11,147,779  

To re-elect Iraj Ali as a Director of the Company.

      10,043,271        63,501        11,137,830  

To re-elect Carsten Boess as a Director of the Company.

      10,029,308        64,801        11,148,293  

To re-elect Bernhard Ehmer as a Director of the Company.

      10,031,806        64,803        11,148,293  

To re-elect Michael Giordano as a Director of the Company.

      10,032,813        63,796        11,148,293  

To re-elect Julie O’Neill as a Director of the Company.

      10,032,238        64,878        11,147,786  

To re-appoint KPMG LLP as UK statutory auditors of the Company, to hold office until the conclusion of the next Annual General Meeting.

      10,128,267        14,515        11,099,620  

To authorize the Company’s Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023.

      10,134,132        16,841        11,093,929  

To receive the UK statutory annual accounts and report for the fiscal year ended 31 December 2022 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2022.

      10,143,307        8,219        11,093,376  

To receive and approve, on a non-binding, advisory basis, the Company’s UK statutory Directors’ Remuneration Report for the year ended December 31, 2022.

      8,424,258        1,700,258        11,120,386  

The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on May 26, 2023 and furnished as Exhibit 99.1 to this Current Report on Form 6-K.

INDEX TO EXHIBITS

 

Number

   

Description

99.1    Notice of Annual General Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ACHILLES THERAPEUTICS PLC
Date: June 29, 2023     By:  

/s/ Robert Coutts

      Robert Coutts
      Chief Financial Officer
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Achilles Therapeutics Charts.
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Achilles Therapeutics Charts.